MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders.
CNS spectrums January 30, 2025 DOI: 10.1017/S1092852925000057 via PubMed
Summary
AI-generated from the abstractMDMA-assisted therapy (MDMA-AT) for PTSD and other behavioral disorders has a controversial history, moving from research to recreational use and back to medicine. Pivotal trials have been conducted, but recent setbacks have hindered clinical application. The chapter argues that MDMA-AT still holds potential to transform psychiatry, though its future is uncertain due to ongoing debates over ethics, methodology, and political influence.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Intervention | MDMA-assisted therapy |
| Topics | Psychedelic-assisted therapy PTSD |
| Keywords | Behavioral disorders FDA MDMA-Assisted Therapy Drug regulation |
| Citations | 5 |
| Key finding | MDMA-assisted therapy holds potential to transform psychiatry despite recent setbacks and ongoing debates over ethics, methodology, and political influence. |
Abstract
This chapter explores the complex and controversial path of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) and other behavioral disorders. It covers MDMA's history from research to recreation to medicine, the pivotal trials, and the challenges faced by researchers. Despite recent setbacks for the clinical application of MDMA, the chapter argues that it holds potential for transforming psychiatry and discusses the uncertain future amidst ongoing debates over ethics, methodology, and political influence.